

Long-Term Postoperative Outcomes in Chronic Rhinosinusitis: BMI-Associated Trends in SNOT-22 Score Improvements

Kaelan Wong^{1,2}, Justin Lau^{1,2}, Mohamad Chaaban MD¹

¹Cleveland Clinic Head and Neck Institute, ²Case Western Reserve University School of Medicine

Background

Chronic rhinosinusitis (CRS) is a persistent inflammatory condition that significantly impacts quality of life and is broadly classified into two phenotypes: CRS with nasal polyps (CRSwNP) and CRS without nasal polyps (CRSsNP).¹ Postoperative recovery following functional endoscopic sinus surgery (FESS) varies widely among patients, and emerging evidence suggests that Body Mass Index (BMI) may influence symptom improvement trajectories.²

Short-term data from our group and others have shown that non-obese CRSwNP patients (BMI <30) tend to experience greater symptomatic relief postoperatively, while obese CRSsNP patients (BMI ≥30) appear to benefit more than their non-obese counterparts.³ However, the durability of these trends beyond the early postoperative period has not been established.

This study investigates whether BMI-associated differences in postoperative symptom improvement persist over time, using longitudinal SNOT-22 scores collected through 52 weeks.

Methods

Study Design & Setting

Prospective observational cohort study conducted at a tertiary academic rhinology clinic from Dec 2021 to Sept 2022.

Patient Population

Adults with CRS undergoing FESS were enrolled. All patients met diagnostic criteria for CRS and had failed maximal medical therapy.

Phenotype & BMI Stratification

Patients were grouped by

- Phenotype: CRSwNP vs CRSsNP
- BMI: <30 (non-obese) vs ≥30 (obese)

Outcome Measures

Change in SNOT-22 score from baseline to multiple time points postoperatively (up to 52 weeks).


Scores were collected at 0, 1, 2, 4, 13, 26, and 52 weeks as available.

Statistical Analysis


Group trends were assessed using mean SNOT-22 deltas over time, comparing obese vs non-obese groups within each phenotype. Differences at specific time points were evaluated for significance ($p < 0.05$).

Results

CRSwNP: Average SNOT-22 Score Delta Over Time



CRSsNP: Average SNOT-22 Score Delta Over Time



- In CRSwNP patients, those with BMI <30 showed consistently greater improvement in SNOT-22 scores compared to patients with BMI ≥30, with the difference sustained through 52 weeks postoperatively.
- In CRSsNP patients, the trend reversed: individuals with BMI ≥30 demonstrated greater and more sustained symptom improvement than their BMI <30 counterparts, persisting through 52 weeks.
- These findings suggest that BMI and CRS phenotype interact to influence long-term surgical outcomes, suggesting a need for BMI-stratified counseling and follow-up.

Conclusion

Long-term follow-up of CRS patients reveals sustained differences in postoperative outcomes based on BMI and disease phenotype. CRSwNP patients with BMI <30 consistently experienced greater symptom improvement up to 52 weeks, while CRSsNP patients with BMI ≥30 showed more favorable outcomes up to 78 weeks.

These opposing trends suggest that BMI may modify inflammatory response and recovery trajectory differently across CRS subtypes. Incorporating BMI into postoperative counseling and future phenotype-specific management strategies may enhance patient outcomes and personalization of care.

References

1. Bachert C, Zhang N, van Zele T, Gevaert P. Chronic rhinosinusitis: from one disease to different phenotypes. *Pediatr Allergy Immunol.* 2012 Aug;23 Suppl 22:2-4. doi: 10.1111/j.1399-3038.2012.01318.x. PMID: 22762847.
2. Nam JS, Roh YH, Fahad WA, Noh HE, Ha JG, Yoon JH, Kim CH, Cho HJ. Association between obesity and chronic rhinosinusitis with nasal polyps: a national population-based study. *BMJ Open.* 2021 May 25;11(5):e047230. doi: 10.1136/bmjopen-2020-047230. PMID: 34035104; PMCID: PMC8154923.
3. Chaaban MR, Asosingh K, Comhair S, Hoying D. Assessing the clinico-immunological profile of patients with obesity and chronic rhinosinusitis. *Int Forum Allergy Rhinol.* 2024;14(6):1036-1045. doi:10.1002/alr.23304